Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Jun 8;18(6):e0286322. doi: 10.1371/journal.pone.0286322

Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings

Md Rabiul Islam 1,*, Md Anamul Haque 1,#, Bulbul Ahamed 1,#, Md Tanbir 1,#, Md Robin Khan 1, Saba Eqbal 1, Md Ashrafur Rahman 2, Mohammad Shahriar 1, Mohiuddin Ahmed Bhuiyan 1
Editor: Christian Napoli3
PMCID: PMC10249809  PMID: 37289746

Abstract

Background

Mpox (monkeypox) infection has become a global concern for healthcare authorities after spreading in multiple non-endemic countries. Following the sudden multi-country outbreak of Mpox, the World Health Organization (WHO) declared a public health emergency of international concern. We do not have any vaccines approved for the prevention of Mpox infection. Therefore, international healthcare authorities endorsed smallpox vaccines for the prevention of Mpox disease. Here we intended to perform this cross-sectional study among the adult males in Bangladesh to assess the Mpox vaccine perception and vaccination intention.

Methods

We conducted this web-based survey among the adult males in Bangladesh from September 1, 2022, to November 30, 2022, using Google Forms. We assessed the Mpox vaccine perception and vaccination intention. We performed a chi-square test to compare vaccine perception and vaccination intention levels. Also, we performed multiple logistic regression analyses to determine the association between the study parameters and the sociodemographic profile of the participants.

Results

According to the present study, the Mpox vaccine perception was high among 60.54% of the respondents. Also, 60.05% of respondents showed medium vaccination intention. Mpox vaccine perception and vaccination intention were strongly associated with the sociodemographic profiles of the participants. Furthermore, we discovered a significant association between the level of education and vaccination intention among the respondents. Also, age and marital status played a role in the Mpox vaccine perception and vaccination intention.

Conclusion

Our findings showed a significant association between sociodemographic characteristics and the Mpox vaccine perception/vaccination intention. Along with the country’s long experience in mass immunization, campaigns about Covid-19 vaccines and high vaccination rates might play a role in Mpox vaccine perception and vaccination intention. We recommend more social awareness and educational communications or seminars for the target population to bring more positive changes in their attitude towards Mpox prevention.

Introduction

The orthopoxvirus genus of the poxviridae family contains the enclosed double-stranded DNA virus known as the Mpox (monkeypox) virus. The Mpox virus is divided into two genetic clades: the Central African (Congo Basin) clade and the West African clade [1, 2]. On November 28, 2022, the World Health Organization (WHO) renamed the disease as Mpox to avoid stigma and racism [3]. Mpox is a zoonotic disease that can be spread to people by direct contact with primates and several rodent species [1]. In 1959, a shipment of sick monkeys from Singapore to a Danish research center led to the first isolation and identification of the Mpox virus. The virus was identified in a child in the Democratic Republic of the Congo who was thought to have smallpox, nevertheless, and it was the first known occurrence of the disease in a human being [4, 5]. However, when it comes to rates of complications, case fatalities, and scarring, Mpox is less severe than smallpox [57]. There have been numerous epidemics of Mpox that were spread from person to person [8, 9]. Transmission through respiratory droplets and direct contact with lesions of an infected person is causing the present outbreak. According to recent data, there is also the possibility of sexual transmission of Mpox [4, 10, 11]. In West African places where there is frequent contact between people and wild animal reservoirs and where there is evidence that the infectious attack rate is rising, Mpox has been identified as a growing public health hazard [5]. The Mpox virus replicates at the site of inoculation after viral entrance by any route (intradermal, nasopharynx, and oropharynx) and subsequently spreads to nearby lymph nodes. According to studies, the incubation period lasts between 5 and 21 days, and signs and symptoms last between 2 and 5 weeks. Fever, headaches, myalgia, lethargy, and lymph node swellings are some of the signs and symptoms that precede the sickness. Rashes of various sizes start from 1 to 5 days after the start of the fever, first on the face, and may or may not spread to other areas of the body [4, 5]. In 2022, there is now a widespread Mpox outbreak across several nations on various continents, primarily affecting the population of men who have sex with men (MSM), bisexual, and gay. In Spain, 99% of the 595 confirmed cases of Mpox were found to be in the MSM population, with the lesions mostly affecting the genital, perianal, and perineal regions. However, this may happen as men often hunt and interact with wild animals [4, 12]. The increase in cases of human Mpox highlights the value of prevention strategies, as well as early screening and identification [13].

Mpox has recently become a global health problem, with the WHO reporting over 80,000 proven and suspected cases in over 90 countries across Europe, the Western Pacific, Southeast Asia, the Americas, and the Eastern Mediterranean. Furthermore, the number of instances likely to grow indefinitely [3, 14, 15]. It has become vital to take preventive measures against Mpox infection by creating social awareness and managing supportive care and symptomatic treatment [16, 17]. Massive health education campaigns are required to raise public awareness and advise infected individuals to remain in isolation, wear protective clothing and surgical masks, as well as refrain from close contact with healthy individuals [9, 18]. Also, safety precautions and quarantine must be maintained for any healthy animal that may have come into close contact with an infected animal and monitored for signs of Mpox for 30 days. These social norms can help prevent the transmission of the Mpox virus from human-to-human [1, 14, 19]. While caring for Mpox patients, healthcare workers must maintain strict hand washing protocol, handle contaminated medical equipment cautiously, sterilize environmental surfaces, and dispose of laundry and garbage appropriately [19]. Individuals with infection should cover the lesions as long as possible until all lesion has spontaneously fallen off to form a new skin layer. Presently, there is no specific effective therapy other than early vaccination following viral exposure [20]. The Centers for Disease Control and Prevention (CDC) states that disease development may halt by getting vaccinated within four days of exposure, and disease severity may fall by injecting a vaccine within 14 days [4]. However, Mpox vaccines are not yet present in Bangladesh and several other countries. Scientists have recommended some smallpox vaccines for preventing the Mpox outbreak as Mpox’s clinical presentation is similar to that of smallpox. According to some research studies, several animal models were vaccinated with smallpox vaccines and provided protection against a variety of orthopoxvirus [21]. Besides, it has been estimated that smallpox vaccines (ACAM2000 and JYNNEOS) provide 85% cross-protection against Mpox disease. However, the risks linked with JYNNEOS are lower than those of ACAM2000. Both smallpox vaccines: ACAM2000, a live-attenuated replicating vaccine, and JYNNEOS, a replication-deficient MVA vaccine, are FDA-approved vaccines to fight against the Mpox virus [14, 22, 23]. Thus, vaccination is the key preventive measure for the Mpox outbreak.

Vaccine hesitancy is recognized as a hazard to public health by the WHO [24]. Misconceptions regarding vaccination abound, and, more crucially, vaccine reluctance is on the rise. In particular, the impact size of vaccinating others is substantially bigger than vaccinating oneself [25, 26]. The fear of vaccinations raises vaccine refusal rates, which increases the chances of illness and death from diseases that may be prevented by vaccines [27]. Prior research has suggested the importance of improving people’s perceptions of their ability to manage their vaccination behavior [28]. Both internal and external factors frequently influence these control-based attitudes, such as the availability of information, resources, willpower, skills, opportunities, sociodemographic differences, vaccine attributes, and speed of vaccine development [26, 29]. However, to roll out vaccines in any country, perception must be good among the potential recipients, and a positive attitude or positive intention must be present toward vaccination [30]. Affective attitude is triggered by emotions and frequently assessed on a continuum of good and bad emotions (e.g., desirable vs undesirable). On the other hand, cognitive attitude is generated by logical judgements and frequently quantified on a continuum of advantages and disadvantages (e.g., safe vs unsafe). Earlier studies revealed that boosting vaccination intention is influenced by enhanced cognitive attitude rather than affective attitude [26]. Furthermore, attention must be drawn to create awareness, willingness, and high positive perceptions among humans for injecting the smallpox vaccine to prevent numerous cases of the Mpox disease. Building public trust in immunization programs requires effective communication between government officials and the public clearly and consistently. This involves describing how vaccines are developed and how they receive regulatory approval based on their safety and effectiveness. Additionally, effective advertisements must emphasize the value of widespread vaccination coverage for achieving community immunity and the duration of protection from vaccinations [31]. The whole purpose of the research study was to determine the perception and intention of the Mpox vaccine among the Bangladeshi adult male population.

Materials and methods

Study design and participants

We conducted a cross-sectional study among the Bangladeshi adult males using Google survey tools from September 1, 2022, to November 30, 2022. A total of 419 students filled out the survey form, but we were only able to analyze 408 responses because 11 of them contained incomplete or inaccurate information. Respondents received the survey form in-person and online via various social media platforms. Only adult males were invited to participate in this study of ages ranging from 18 to 45 years as this age is vulnerable to the Mpox virus. Moreover, several data studies around the world showed 98% of confirmed cases of Mpox disease among 18–45 years of males. Therefore, we excluded females of all ages. All participants who were male Bangladeshi ethnicity and residents provided electronic consent. Participation in this study was entirely voluntary.

Estimations

The goal was to estimate the relationships between the participants’ sociodemographic profile, vaccine perception, and vaccination intention. Accordingly, we prepared a self-reported semi-structured questionnaire in English and translated it into Bangla for better understanding and clarity. We then conducted a pilot study among a small, randomly chosen group of participants to confirm that the survey questions were comprehensible and readable.

Assessment tools

We used three different tools to assess the participants’ sociodemographic profile, vaccine perception, and vaccination intention. The sociodemographic variables included age, marital status, gender, occupation, sexual orientation, body mass index, living status, smoking habit, information about sexual partner and the impact of Covid-19 pandemic on their personal and social life. Simultaneously, we asked six questions regarding vaccine perception and three regarding vaccination intention. Each individual responded to the nine questions under five options: totally disagree (0), disagree (1), neutral (2), agree (3), and totally agree (4).

Statistical analysis

We processed and analyzed the data with the help of Statistical Packages for Social Sciences, SPSS (version 25.0). Furthermore, we employed descriptive statistical techniques to analyze the demographics and variations among the respondent. Subsequently, for data editing, coding, sorting, classification, and tabulation, we used Microsoft Excel 2016. The chi-square test helped to determine the consequences of the Mpox outbreak with vaccination and other relevant parameters. Regression analysis was performed to measure the association of vaccine perception and vaccination intention with different sociodemographic profiles of the participants. A p-value of 0.05 or below was considered significant in the test results.

Ethics

The protocol was approved by the Research Ethics Committee, University of Asia Pacific, Dhaka, Bangladesh (Ref: UAP/REC/2022/l09(S1). We conducted this study following the principles stated in the Declaration of Helsinki. Also, we obtained informed electronic consent from all the participants.

Results

We displayed the demographics of the research participants in Table 1. Almost half of the respondents were between (18–25) years of age and had a normal BMI of 65%. Moreover, among the 408 participants, 61% were unmarried, living with family (76%), non-smokers (68%), and 41% were graduates or above. We discovered that nearly 99% of the participants were heterosexual, and 93% belonged to a lower economic class. Also, most of them (73%) had no impact of Covid-19 on their life and 60% had no sexual partners.

Table 1. Distribution of sociodemographic profiles among the respondents.

Total, N = 408 n %
Age range (years)
    18–25 209 51.2
    26–35 155 38.0
    36–45 44 10.8
BMI (kg/m 2 )
    Below 18.5 35 8.6
    18.5–25 266 65.2
    Above 25 107 26.2
Marital status
    Unmarried 252 61.8
    Married 156 38.2
Education level
    Illiterate 27 6.6
    Primary 37 9.1
    Secondary 58 14.2
Higher Secondary 117 28.7
    Graduate/above 169 41.4
Occupation
    Service 129 31.6
    Business 55 13.5
    Self-employed 41 10.1
    Student 145 35.5
    Unemployed 23 5.6
    Others 15 3.7
Economic status
    Low 379 92.9
    Medium 20 4.9
    High 9 2.2
Residence
    Urban 275 67.4
    Rural 133 32.6
Living status
    With family 311 76.2
    Without family 97 23.8
Smoking habit
    Smoker 131 32.1
    Non-smoker 277 67.9
Sexual orientation
    Heterosexual 405 99.3
    Bisexual 1 0.2
    Homosexual 2 0.5
Sexual partner
    None 246 60.3
    One 144 35.3
    More than one 18 4.4
Covid-19 impact on life
Yes 110 27.0
No 298 73.0

BMI, body mass index; N, number.

According to Fig 1, the prevalence of Mpox vaccine perception among the respondents was observed to be (i) low (1.47%), (ii) medium (37.99%), and (iii) high (60.54%).

Fig 1. Level of Mpox (monkeypox) vaccine perception and vaccination intention among the respondents.

Fig 1

Also, the prevalence of vaccination intention among the participants was observed to be (i) low (3.68%), (ii) medium (60.05%), and (iii) high (36.27%). We have noticed a correlation between various sociodemographic factors with vaccine perception and vaccination intention. The frequency of vaccine perception is higher in (i) individuals who are graduates/above versus higher secondary (51% versus 27.5%, p<0.001), (ii) unmarried versus married (69.6% versus 30.4, p<0.001), (iii) aged (years) 18–25 versus 26–35 (54.7% versus 38.4%, p<0.001), (iv) low versus medium economic status (93.9% versus 3.2%, p<0.001), (v) BMI of (18.5–25) kg/m2 versus above 25 kg/m2 (64.8% versus 24.7%, p<0.001), (vi) heterosexual versus homosexual (99.2% versus 0.4%, p<0.001), (vii) having no sexual partner versus having one (68.9% versus 27.9%, p<0.001), (viii) living with a family versus without family (70.4% versus 29.6%, p<0.001), and (ix) residing in an urban area versus rural area (75.3% versus 24.7%, p<0.001), respectively. Also, 67.2% of the participants disagreed with having an impact of COVID-19 on their lives but the rest 32.8% agreed (Table 2).

Table 2. Association between the level of Mpox (monkeypox) vaccine perception and sociodemographic profiles of the respondents.

Parameters Mpox (monkeypox) vaccine perception
High, N = 247 Medium, N = 155 Low, N = 6 Chi-square tests
n % n % n % χ2 df p-value
Age range (years)
    18–25 135 54.7 70 45.2 4 66.7 585.378 9 <0.001
    26–35 95 38.4 58 37.4 2 33.3
    36–45 17 6.9 27 17.4 0 0.0
BMI (kg/m 2 )
    Below 18.5 26 10.5 8 5.2 1 16.6 581.914 9 <0.001
    18.5–25 160 64.8 105 67.7 1 16.7
    Above 25 61 24.7 42 27.1 4 66.7
Marital status
    Unmarried 172 69.6 75 48.4 5 83.3 599.316 9 <0.001
    Married 75 30.4 80 51.6 1 16.7
Education level
    Illiterate 11 4.5 16 10.3 0 0.0 618.183 15 <0.001
    Primary 17 6.9 20 12.9 0 0.0
    Secondary 25 10.1 33 21.3 0 0.0
Higher Secondary 68 27.5 45 29.0 4 66.7
    Graduate/above 126 51.0 41 26.5 2 33.3
Occupation
    Service 70 28.3 58 37.4 1 16.7 606.049 18 <0.001
    Business 34 13.8 21 13.5 0 0.0
    Self-employed 19 7.7 22 14.2 0 0.0
    Student 101 40.9 39 25.2 5 83.3
    Unemployed 18 7.3 5 3.2 0 0.0
    Others 5 2.0 10 6.5 0 0.0
Economic status
    Low 232 93.9 141 91.0 6 100.0 575.690 9 <0.001
    Medium 8 3.2 12 7.7 0 0.0
    High 7 2.9 2 1.3 0 0.0
Residence
    Urban 186 75.3 84 54.2 5 83.3 596.843 9 <0.001
    Rural 61 24.7 71 45.8 1 16.7
Living status
    With family 174 70.4 131 84.5 6 100.0 588.290 9 <0.001
    Without family 73 29.6 24 15.5 0 0.0
Smoking habit
    Smoker 69 27.9 61 39.4 1 16.7 583.644 9 <0.001
    Non-smoker 178 72.1 94 60.6 5 83.3
Sexual orientation
    Heterosexual 245 99.2 155 100.0 5 83.3 614.832 9 <0.001
    Bisexual 1 0.4 0 0.0 0 0.0
    Homosexual 1 0.4 0 0.0 1 16.7
Sexual partner
    None 170 68.9 73 47.1 3 50.0 597.201 9 <0.001
    One 69 27.9 73 47.1 2 33.3
    More than one 8 3.2 9 5.8 1 16.7
Covid-19 impact on life
    Yes 81 32.8 27 17.4 2 33.3 584.089 6 <0.001
    No 166 67.2 128 82.6 4 66.7

p-values are significant at 95% confidence interval (p<0.05). Significant p-values are shown in bold. BMI, body mass index; df, degrees of freedom; N, number.

We used the binary logistic regression method to measure the correlations between various parameters and vaccine perception (Table 3).

Table 3. Regression analysis of variables by the level of Mpox (monkeypox) vaccine perception among the respondents.

  High vaccine perception, N = 247 Medium vaccine perception, N = 155 Low vaccine perception, N = 6
  OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Age range (years)
    18–25 0.694 0.223–2.155 0.527 0.791 0.117–5.363 0.811 0.419 0.021–8.540 0.572
    26–35 1.305 0.503–3.384 0.585 1.161 0.227–5.945 0.858 0.455 0.033–6.324 0.557
    36–45 1 1 1
BMI (kg/m 2 )
    18.5–25 0.393 0.134–1.151 0.088 0.537 0.096–2.998 0.479 0.023 0.004–0.152 <0.001
    Above 25 0.329 0.101–1.074 0.066 0.502 0.075–3.356 0.477 0.349 0.053–2.284 0.272
    Below 18.5 1 1 1
Marital status
    Married 0.988 0.305–3.207 0.984 0.909 0.123–6.697 0.925 0.002 0.000–0.038 <0.001
    Unmarried 1 1 1
Education level
    Illiterate 1.542 0.358–6.642 0.561 1.319 0.113–15.381 0.825 2.701 0.005–1411.784 0.756
    Primary 1.075 0.379–3.048 0.892 1.044 0.174–6.261 0.962 0.972 0.033–28.447 0.987
Higher Secondary 1.999 0.877–4.560 0.100 1.570 0.385–6.399 0.529 8.687 0.792–95.263 0.077
    Graduate/above 3.718 1.518–9.105 0.004 2.218 0.485–10.137 0.304 1.129 0.079–16.124 0.929
    Secondary 1 1 1
Occupation
    Service 0.434 0.122–1.540 0.196 0.601 0.077–4.661 0.626 0.777 0.031–19.582 0.878
    Business 0.959 0.230–4.001 0.954 0.950 0.093–9.687 0.966 0.179 0.003–9.190 0.392
    Self-employed 0.323 0.072–1.448 0.140 0.489 0.041–5.769 0.570 0.114 0.001–8.996 0.330
    Student 0.641 0.180–2.283 0.493 0.792 0.103–6.085 0.823 11.532 0.424–313.367 0.147
    Others 0.195 0.029–1.289 0.090 0.335 0.015–7.543 0.491 0.362 0.811–1.025 0.176
    Unemployed 1 1 1
Economic status
    Low 3.336 1.031–10.792 0.044 2.097 0.289–15.219 0.464 2.151 0.084–55.140 0.643
    High 3.611 0.422–30.870 0.241 2.192 0.067–72.159 0.660 1.658 0.007–401.176 0.857
    Medium 1 1 1
Residence
    Urban 1.919 0.163–22.587 0.604 1.433 0.030–68.257 0.855 0.096 0.000–85.245 0.498
    Rural 1 1 1
Living status
    With family 1.275 0.521–3.232 0.671 1.568 0.371–7.390 1.395 29.641 2.944–303.099 0.328
    Without family 1 1 1
Smoking habit
    Non-smoker 1.030 0.557–1.904 0.925 1.034 0.367–2.915 0.949 2.909 0.604–13.997 0.183
    Smoker 1 1 1
Sexual partner
    None 2.012 0.619–6.541 0.245 1.382 0.188–10.183 0.751 0.432 0.051–0.973 <0.001
    More than one 1.578 0.352–7.065 0.551 1.389 0.109–17.657 0.800 35.868 0.469–274.081 0.106
    One 1 1 1
Covid-19 impact on life
    No 0.712 0.372–1.361 0.304 0.814 0.280–2.369 0.706 0.997 0.280–3.545 0.996
    Yes 1 1 1

p-values are significant at 95% confidence interval (p<0.05). Significant p-values are shown in bold. BMI, Body Mass Index; CI, Confidence Interval; N, Number; OR, Odds Ratio.

Moreover, the proportion of vaccination intention is at a medium level for (i) BMI (kg/m2) of 18.5–25 versus above 25 (64.9% versus 28.6%, p<0.001), (ii) aged (years) 18–25 versus 26–35 (50.2% versus 36.7%, p<0.001), (iii) individuals who are graduate/above versus higher secondary (35.5% versus 26.5%, p<0.001), (iv) low versus medium economic status (92.2% versus 6.6%, p<0.001), (v) non-smoker versus smoker (64.1% versus 35.9%, p<0.001), (vi) student versus service holder (34.3% versus 29.8%, p<0.001), and (vii) having no sexual partner versus having one (56.8% versus 37.1%, p<0.001), respectively. Additionally, 23.3% of the people involved in the survey agreed that COVID-19 had an impact on their lives, while the remaining 76.7% disagreed (Table 4).

Table 4. Association between the level of Mpox (monkeypox) vaccination intention and sociodemographic profiles of the respondents.

Parameters Mpox (monkeypox) vaccination intention
High, N = 148 Medium, N = 245 Low, N = 15 Chi-square tests
n % n % n % χ2 df p-value
Age range (years)
    18–25 76 51.3 123 50.2 10 66.7 576.653 9 <0.001
    26–35 62 41.9 90 36.7 3 20.0
    36–45 10 6.8 32 13.1 2 13.3
BMI (kg/m 2 )
    Below 18.5 17 11.5 16 6.5 2 13.3 574.303 9 <0.001
    18.5–25 98 66.2 159 64.9 9 60.0
    Above 25 33 22.3 70 28.6 4 26.7
Marital status
    Unmarried 101 68.2 141 57.6 10 66.7 576.411 9 <0.001
    Married 47 31.8 104 42.4 5 33.3
Education level
    Illiterate 3 2.0 22 9.0 2 13.3 614.163 15 <0.001
    Primary 12 8.1 25 10.2 0 0.0
    Secondary 8 5.4 46 18.8 4 26.7
Higher Secondary 46 31.1 65 26.5 6 40.0
    Graduate/above 79 53.4 87 35.5 3 20.0
Occupation
    Service 51 34.5 73 29.8 5 33.3 593.913 18 <0.001
    Business 16 10.8 39 15.9 0 0.0
    Self-employed 12 8.1 28 11.4 1 6.7
    Student 55 37.1 84 34.3 6 40.0
    Unemployed 10 6.8 13 5.3 0 0.0
    Others 4 2.7 8 3.3 3 20.0
Economic status
    Low 138 93.2 226 92.2 15 100.0 578.174 9 <0.001
    Medium 4 2.7 16 6.6 0 0.0
    High 6 4.1 3 1.2 0 0.0
Residence
Urban 108 73.0 155 63.3 12 80.0 578.038 9 <0.001
Rural 40 27.0 90 36.7 3 20.0
Living status
    With family 102 68.9 195 79.6 14 93.3 580.909 9 <0.001
    Without family 46 31.1 50 20.4 1 6.7
Smoking habit
    Smoker 38 25.7 88 35.9 5 33.3 574.733 9 <0.001
    Non-smoker 110 74.3 157 64.1 10 66.7
Sexual orientation
    Heterosexual 145 98.0 245 100.0 15 100.0 575.391 9 <0.001
    Bisexual 1 0.7 0 0.0 0 0.0
    Homosexual 2 1.3 0 0.0 0 0.0
Sexual partner
    None 99 66.9 139 56.8 8 53.3 578.441 9 <0.001
    One 47 31.8 91 37.1 6 40.0
    More than one 2 1.3 15 6.1 1 6.7
Covid-19 impact on life
    Yes 49 33.1 57 23.3 4 26.7 574.320 6 <0.001
    No 99 66.9 188 76.7 11 73.3

p-values are significant at 95% confidence interval (p<0.05). Significant p-values are shown in bold. BMI, body mass index; df, degrees of freedom; N, number.

Similar to Mpox vaccine perception, we also assessed the associations between vaccination intention and sociodemographic parameters (Table 5). Respondents with BMI (kg/m2) above 25 had 1.32 times more low vaccination intention than below 18.5 (OR = 1.32, 95% CI = 0.14 to 12.04, p = 0.808). Participants residing in the urban area had high vaccination intention of 2.79 times greater than those in rural area (OR = 2.79, 95% CI = 0.39 to 20.03, p = 0.309). Also, the likelihood of having low vaccination intention with no sexual partner was half than with one partner (OR = 0.50, 95% CI = 0.07 to 3.76, p = 0.502).

Table 5. Regression analysis of variables by the level of Mpox (monkeypox) vaccination intention among the respondents.

  High vaccination intention, N = 148 Medium vaccination intention, N = 245 Low vaccination intention, N = 15
  OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Age range (years)
    18–25 0.617 0.190–2.011 0.423 0.812 0.032–20.357 0.899 0.910 0.106–7.822 0.932
    26–35 0.883 0.038–2.534 0.817 0.941 0.056–15.711 0.966 0.711 0.133–0.686 0.689
    36–45 1 1 1
BMI (kg/m 2 )
    18.5–25 0.695 0.301–1.604 0.394 1.074 0.075–15.402 0.958 1.225 0.158–9.488 0.846
    Above 25 0.407 0.157–1.054 0.064 0.906 0.048–17.115 0.948 1.316 0.144–12.035 0.808
    Below 18.5 1 1 1
Marital status
    Married 0.781 0.283–2.150 0.632 0.894 0.051–15.574 0.939 0.573 0.075–4.354 0.590
    Unmarried 1 1 1
Education level
    Illiterate 0.788 0.136–4.558 0.790 0.952 0.013–67.902 0.982 0.772 0.027–22.460 0.880
    Primary 2.771 0.828–9.276 0.098 1.690 0.073–39.090 0.743 14.746 2.163–100.541 0.006
    Graduate/above 5.216 1.943–14.001 0.001 2.015 0.159–25.556 0.589 0.213 0.028–1.615 0.135
Higher Secondary 4.249 1.676–10.768 0.002 1.764 0.166–18.706 0.673 0.944 0.172–5.170 0.947
    Secondary 1 1 1
Occupation
    Service 1.162 0.416–3.244 0.775 1.046 0.051–21.414 0.977 6.980 0.058–841.881 0.427
    Business 0.932 0.282–3.084 0.909 1.009 0.032–31.388 0.996 0.568 0.003–93.877 0.828
    Self-employed 1.013 0.276–3.715 0.984 1.049 0.024–45.356 0.980 2.966 0.017–513.861 0.679
    Student 0.726 0.267–1.980 0.532 0.911 0.049–17.100 0.950 5.854 0.046–738.038 0.474
    Others 0.379 0.082–1.756 0.215 0.484 0.128–1.828 0.284 1.064 0.322–3.522 0.919
    Unemployed 1 1 1
Economic status
    Low 2.668 0.771–9.236 0.121 1.464 0.062–34.475 0.813 5.609 0.141–222.888 0.359
    High 5.071 0.288–89.163 0.267 1.325 0.961–5.815 0.956 6.681 2.877–50.275 0.003
    Medium 1 1 1
Residence
    Urban 2.785 0.387–20.028 0.309 1.280 0.002–720.406 0.939 0.152 0.000–91.323 0.564
    Rural 1 1 1
Living status
    With family 1.198 0.577–2.566 0.356 1.671 0.209–16.408 1.739 2.488 0.514–13.796 0.720
    Without family 1 1 1
Smoking habit
    Non-smoker 1.122 0.608–2.071 0.712 1.017 0.189–5.465 0.984 1.679 0.459–6.134 0.433
    Smoker 1 1 1
Sexual partner
    None 0.865 0.326–2.296 0.771 0.955 0.061–14.966 0.974 0.502 0.067–3.762 0.502
    More than one 0.420 0.070–2.506 0.341 0.667 0.012–35.869 0.842 1.587 0.205–12.309 0.659
    One 1 1 1
Covid-19 impact on life
    No 0.867 0.496–1.516 0.618 0.930 0.179–4.830 0.932 0.702 0.221–2.232 0.548
    Yes 1 1 1

p-values are significant at 95% confidence interval (p<0.05). Significant p-values are shown in bold. BMI, Body Mass Index; CI, Confidence Interval; N, Number; OR, Odds Ratio.

Respondents who were (26–35) years old had 1.31 times more high vaccine perception than (36–45) years old (OR = 1.31, 95% CI = 0.50 to 3.38, p = 0.585). The likelihood of having high vaccine perception with no sexual partner was double than with one partner (OR = 2.01, 95% CI = 0.62 to 6.54, p = 0.245). Moreover, participants who had no COVID-19 impact on life were 0.71 times less likely to have high vaccine perception than those who had impact on life (OR = 0.71, 95% CI = 0.372 to 1.36, p = 0.304).

Discussion

As far as we are aware, this is the first study to evaluate the Mpox vaccine perception and vaccination intention of the Bangladeshi adult male population. Significantly, our study findings indicate that education level, age range, marital status, sexual orientation, economic and living status, smoking habit, BMI, residence, Covid-19 impact on life, and the number of sexual partners play a key role in determining the level of vaccine perception and vaccination intention. Most of the respondents showed a higher level of vaccine perception but a medium level of vaccination intention. Moreover, all the sociodemographic factors with Mpox vaccine perception and vaccination intention are found to be significantly associated.

Currently, the incidence of Mpox is dramatically increasing. Originally, Mpox was an endemic zoonotic disease that was restricted to Central and West African countries. Earlier in 2022, in countries where Mpox had never existed before, it began to rise [32]. So, to prevent the spread of the Mpox virus, perception and intention towards vaccination must be strong. According to a similar study in Saudi Arabia, the majority of the participants suggested implementing a preventive measure and to start a vaccination campaign to minimize the spread of Mpox disease. They assessed the vaccination intention with various sociodemographic profiles such as (i) age (18 years and above), (ii) both genders, (iii) marital status (divorced, married, single, widowed), (iv) socioeconomic status, (v) educational level, and (vi) region [32]. A cross-sectional survey in Pakistan reported that the association between attitude and knowledge with the region of respondents, sex, and type of academic degree toward Mpox were significant [33]. A study in Italy found that the participants had significant knowledge gaps on various factors of Mpox [34]. Another study among 1,352 Italian adults reported that only 26.7% of the respondents were aware about Mpox burden, 47.1% did not have idea about viral transmission, 48.9% were unaware about symptoms, 54.2% were hesitant toward Mpox vaccination, and 38.5% were not confident about vaccines [35]. Nevertheless, respondents of a European study reported higher vaccination intention as they were well aware of the Mpox infection [36]. According to a survey of the general population in the United States, 46% of the respondents were willing to be vaccinated against Mpox [37]. Another study revealed that 77.3% of Indonesian internal medicine residents intended to receive the Mpox vaccine [33]. Initially, many previous studies had shown that there was low vaccination intention among the Bangladeshi population to fight against the Covid-19 virus. More than 50% of the participants were unaware of the effectiveness of the Covid-19 vaccine [38]. Some significant barriers to vaccine hesitancy have been identified, including a lack of faith on the authorities, vaccine-origin conspiracy theories, and misconceptions about religion [39, 40]. Vaccine hesitancy was identified as a serious public health threat by the WHO, raising concerns about the global success of vaccination [39, 41]. Initially, despite having negative perceptions toward a vaccine, later vaccination adequacy increased by creating awareness through several campaigns.

In an Italian study, they had involved 566 physicians only but we involved 408 participants from several occupations [34]. The studies were conducted with both male and female participants in Pakistan and Saudi Arabia but we had performed with only male participants as they are the most affected by the Mpox virus according to several studies [13, 33]. The Pakistani research study involved both healthcare and non-healthcare students as participants. In the European study, large groups of people from different regions of Europe provided the data via smartphone-based online gay-dating apps but we gathered the data from those participants who lived in Bangladesh [42]. However, older respondents of our study as well as European study were more likely to accept vaccinations. According to a similar previous study, the Covid-19 vaccination study was performed among public university students [38]. In both of our studies, the level of education appeared to have a significant impact on the perception and intention toward the vaccine. However, we conducted this study with half of the participants than they did. Moreover, none of the studies assessed the vaccine perception and vaccination intention with sexual orientation, number of sexual partners, and Covid-19 impact on life.

Overall, Bangladeshi participants in this study declared higher perceptions and intentions towards vaccination than other countries such as USA, Europe, and Italy. According to several previous studies regarding the Covid-19 vaccine, the perception and intention of getting injected with the Mpox vaccine rose [13, 33, 34, 38, 42]. Thus, we hope that the Mpox vaccine perception and vaccination intention will also further rise. In Bangladesh, vaccination campaigns have been setup in many locations to create awareness of the disease and prevent the spread of the virus [4350]. Hence, they have high knowledge about the importance of immunization. So, to get a more effective result, participants from other countries could also follow the same pattern to prevent the spread of the virus among the vast population. Therefore, effective vaccination strategies are necessary. Notably, perception and intention toward different vaccines, along with the degree of misinformation and trust, are likely to change over time; as a result, they need to be evaluated frequently, given their changing nature.

Several limitations apply to the findings in this report. Due to the increased familiarity with the internet and social media, and the proactive attitude toward providing personal details through these platforms, some sub-groups may unintentionally be over-sampled. Similarly, it would be difficult for people to respond if they lack an internet connection in their area, and therefore, some may provide partial information or misinformation. It may be difficult for some of the respondents to understand the questions online, but they may have understood the questions with clarity if interviewed in-person. Also, we included only adult males that might be considered as selection bias of this study. Nonetheless, our study design does have some advantages. Online surveying made it possible to reach a broad spectrum of people in a short time and obtained data that closely matches the characteristics of the larger population that helped to obtain a more conclusive result. By keeping the identity of the participants anonymous or confidential, many participants consequently felt more comfortable providing truthful responses. It became easy for the respondents to complete the online survey form at any time and from any location, whilst the scenario was opposite through in-person data collection. Moreover, we prepared a structured survey questionnaire in English and translated it into Bangla for better comprehension and clarity for the respondents.

To determine the Mpox vaccine perception and vaccination intention among the Bangladeshi male population, a case-control study could be performed in the future to minimize the limitation. More Mpox vaccination research is required to understand the perception and intention of the healthcare professionals such as physicians, pharmacists, and psychologists as they are at a higher risk of exposure.

Conclusion

Our research study highlighted an incline in vaccine perception and vaccination intention among adult males of Bangladesh to prevent Mpox disease. In groups where there are signs of lower perception and intention, it is important to take steps to increase both the perception and intention of the Mpox vaccination. Additionally, there was a strong correlation between vaccine perception and vaccination intention of the respondents with various sociodemographic profiles such as the level of education, sexual orientation, number of sexual partners, age range, residents living in an urban or rural area, Covid-19 impact on life, smoking habit, occupation, economic status, BMI, and living status. Nevertheless, our research demonstrated that sociodemographic profiles are significantly related to vaccination hesitancy. As a result, it is essential to create awareness regarding the Mpox vaccine through campaigns. Researchers, practitioners, and policymakers may find our research study helpful for raising the knowledge of the vaccine and vaccination status against Mpox. Adult males of the Bangladeshi population must be immunized as soon as possible to combat this disease.

Supporting information

S1 File

(XLSX)

Acknowledgments

All the authors are thankful to the participants for their cooperation in this study.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.World Health Organization. Monkeypox. 2022. https://www.who.int/news-room/fact-sheets/detail/monkeypox. Accessed on January 2, 2023.
  • 2.Zardi EM, Chello C. Human Monkeypox-A Global Public Health Emergency. Int J Environ Res Public Health. 2022;19(24):16781. Published 2022 Dec 14. doi: 10.3390/ijerph192416781 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.United Nations. WHO recommends new name for monkeypox. 2022. https://news.un.org/en/story/2022/11/1131082. Accessed on January 3, 2023. [Google Scholar]
  • 4.Moore MJ, Rathish B, Zahra F. Mpox (Monkeypox). In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 30, 2022. [PubMed] [Google Scholar]
  • 5.Petersen E, Kantele A, Koopmans M, et al. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis Clin North Am. 2019;33(4):1027–1043. doi: 10.1016/j.idc.2019.03.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis [published correction appears in Lancet Infect Dis. 2004 Apr;4(4):251]. Lancet Infect Dis. 2004;4(1):15–25. doi: 10.1016/s1473-3099(03)00856-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Russo AT, Berhanu A, Bigger CB, et al. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2020;38(3):644–654. doi: 10.1016/j.vaccine.2019.10.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Islam MR, Asaduzzaman M, Shahriar M, Bhuiyan MA. The spreading of monkeypox in nonendemic countries has created panic across the world: Could it be another threat?. J Med Virol. 2023;95(1):e27919. doi: 10.1002/jmv.27919 [DOI] [PubMed] [Google Scholar]
  • 9.Sohan M, Akter MS, Islam MR. Expedition of monkeypox virus from Africa to rest of the world: What has made this old foe so powerful?. Ann Med Surg (Lond). 2022;82:104688. Published 2022 Sep 15. doi: 10.1016/j.amsu.2022.104688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Islam MR, Nowshin DT, Khan MR, Shahriar M, Bhuiyan MA. Monkeypox and sex: Sexual orientations and encounters are key factors to consider. Health Sci Rep. 2023;6(1):e1069. Published 2023 Jan 19. doi: 10.1002/hsr2.1069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hraib M, Jouni S, Albitar MM, Alaidi S, Alshehabi Z. The outbreak of monkeypox 2022: An overview. Ann Med Surg (Lond). 2022. Jun 24;79:104069. doi: 10.1016/j.amsu.2022.104069 ; PMCID: PMC9289401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kava CM, Rohraff DM, Wallace B, et al. Epidemiologic Features of the Monkeypox Outbreak and the Public Health Response—United States, May 17-October 6, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(45):1449–1456. Published 2022 Nov 11. doi: 10.15585/mmwr.mm7145a4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Alshahrani NZ, Alzahrani F, Alarifi AM, et al. Assessment of Knowledge of Monkeypox Viral Infection among the General Population in Saudi Arabia. Pathogens. 2022;11(8):904. Published 2022 Aug 11. doi: 10.3390/pathogens11080904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Dou YM, Yuan H, Tian HW. Monkeypox virus: past and present [published online ahead of print, 2022 Oct 10]. World J Pediatr. 2022;1–7. doi: 10.1007/s12519-022-00618-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.See KC. Vaccination for Monkeypox Virus Infection in Humans: A Review of Key Considerations. Vaccines (Basel). 2022;10(8):1342. Published 2022 Aug 18. doi: 10.3390/vaccines10081342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chowdhury PPD, Haque MA, Ahamed B, Tanbir M, Islam MR. A Brief Report on Monkeypox Outbreak 2022: Historical Perspective and Disease Pathogenesis. Clin Pathol. 2022;15:2632010X221131660. Published 2022 Oct 21. doi: 10.1177/2632010X221131660 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Akter MS, Sohan M, Islam MR. The rapid spreading of monkeypox virus is a threat for global public health: What should we do to fight this old enemy?. Health Sci Rep. 2022;5(6):e876. Published 2022 Oct 4. doi: 10.1002/hsr2.876 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Rabiul Islam M, Hasan M, Rahman MS, Rahman MA. Monkeypox outbreak—No panic and stigma; Only awareness and preventive measures can halt the pandemic turn of this epidemic infection. Int J Health Plann Manage. 2022;37(5):3008–3011. doi: 10.1002/hpm.3539 [DOI] [PubMed] [Google Scholar]
  • 19.Di Gennaro F, Veronese N, Marotta C, et al. Human Monkeypox: A Comprehensive Narrative Review and Analysis of the Public Health Implications. Microorganisms. 2022;10(8):1633. Published 2022 Aug 12. doi: 10.3390/microorganisms10081633 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Islam MR, Hossain MJ, Roy A, et al. Repositioning potentials of smallpox vaccines and antiviral agents in monkeypox outbreak: A rapid review on comparative benefits and risks [published correction appears in Health Sci Rep. 2022. Nov 01;5(6):e897]. Health Sci Rep. 2022;5(5):e798. Published 2022 Aug 23. doi: 10.1002/hsr2.798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Khan MR, Hossain MJ, Roy A, Islam MR. Decreasing trend of monkeypox cases in Europe and America shows hope for the world: Evidence from the latest epidemiological data. Health Sci Rep. 2022;6(1):e1030. Published 2022 Dec 29. doi: 10.1002/hsr2.1030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Farasani A. Monkeypox virus: Future role in Human population [published online ahead of print, 2022 Oct 12]. J Infect Public Health. 2022;15(11):1270–1275. doi: 10.1016/j.jiph.2022.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Abdelaal A, Reda A, Lashin BI, et al. Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?. Vaccines (Basel). 2022;10(9):1419. Published 2022 Aug 29. doi: 10.3390/vaccines10091419 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ether SA, Emon FA, Roknuzzaman A, Rakibuzzaman M, Rahman FI, Islam MR. A cross-sectional study of COVID-19-related knowledge, risk perceptions, and preventive practices among pharmacy students in Bangladesh. SAGE Open Med. 2022;10:20503121211073014. Published 2022 Jan 18. doi: 10.1177/20503121211073014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bari MS, Hossain MJ, Ahmmed F, et al. Knowledge, Perception, and Willingness towards Immunization among Bangladeshi Population during COVID-19 Vaccine Rolling Period. Vaccines (Basel). 2021;9(12):1449. Published 2021 Dec 7. doi: 10.3390/vaccines9121449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Xiao X, Wong RM. Vaccine hesitancy and perceived behavioral control: A meta-analysis. Vaccine. 2020;38(33):5131–5138. doi: 10.1016/j.vaccine.2020.04.076 [DOI] [PubMed] [Google Scholar]
  • 27.Ropeik D. How society should respond to the risk of vaccine rejection. Hum Vaccin Immunother. 2013;9(8):1815–1818. doi: 10.4161/hv.25250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Islam MR, Hasan M, Nasreen W, Tushar MI, Bhuiyan MA. The COVID-19 vaccination experience in Bangladesh: Findings from a cross-sectional study. Int J Immunopathol Pharmacol. 2021;35:20587384211065628. doi: 10.1177/20587384211065628 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Al-Amer R, Maneze D, Everett B, et al. COVID-19 vaccination intention in the first year of the pandemic: A systematic review. J Clin Nurs. 2022;31(1–2):62–86. doi: 10.1111/jocn.15951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Islam MR. Urgent call for mass immunization against coronavirus in Bangladesh. Sci Prog. 2021;104(4):368504211058562. doi: 10.1177/00368504211058562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review. Front Public Health. 2021;9:698111. Published 2021 Aug 13. doi: 10.3389/fpubh.2021.698111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nations United. Monkeypox declared a global health emergency by the World Health Organization. 2022. https://news.un.org/en/story/2022/07/1123152. Accessed on February 10, 2023. [Google Scholar]
  • 33.Kumar N, Ahmed F, Raza MS, et al. Monkeypox Cross-Sectional Survey of Knowledge, Attitudes, Practices, and Willingness to Vaccinate among University Students in Pakistan. Vaccines (Basel). 2022;11(1):97. Published 2022 Dec 31. doi: 10.3390/vaccines11010097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Riccò M, Ferraro P, Camisa V, et al. When a Neglected Tropical Disease Goes Global: Knowledge, Attitudes and Practices of Italian Physicians towards Monkeypox, Preliminary Results. Trop Med Infect Dis. 2022;7(7):135. Published 2022 Jul 14. doi: 10.3390/tropicalmed7070135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gallè F, Bianco L, Da Molin G, et al. "Monkeypox: What Do You Know about That?" Italian Adults’ Awareness of a New Epidemic. Pathogens. 2022;11(11):1285. Published 2022 Nov 1. doi: 10.3390/pathogens11111285 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Reyes-Urueña J, D’Ambrosio A, Croci R, et al. High monkeypox vaccine acceptance among male users of smartphone-based online gay-dating apps in Europe, 30 July to 12 August 2022. Euro Surveill. 2022;27(42):2200757. doi: 10.2807/1560-7917.ES.2022.27.42.2200757 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Winters M, Malik AA, Omer SB. Attitudes towards Monkeypox vaccination and predictors of vaccination intentions among the US general public. PLoS One. 2022;17(12):e0278622. Published 2022 Dec 1. doi: 10.1371/journal.pone.0278622 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hossain ME, Islam MS, Ghose TK, et al. COVID-19 vaccine acceptability among public university students in Bangladesh: Highlighting knowledge, perceptions, and attitude. Hum Vaccin Immunother. 2021;17(12):5089–5098. doi: 10.1080/21645515.2021.2010426 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Patwary MM, Bardhan M, Al Imran S, et al. Psychological determinants of COVID-19 vaccine acceptance among urban slum dwellers of Bangladesh. Front Public Health. 2022;10:958445. Published 2022 Sep 16. doi: 10.3389/fpubh.2022.958445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wang Q, Yang L, Jin H, Lin L. Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. Prev Med. 2021;150:106694. doi: 10.1016/j.ypmed.2021.106694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Nossier SA. Vaccine hesitancy: the greatest threat to COVID-19 vaccination programs. J Egypt Public Health Assoc. 2021;96(1):18. Published 2021 Jul 5. doi: 10.1186/s42506-021-00081-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Dukers-Muijrers NHTM, Evers Y, Widdershoven V, et al. Mpox vaccination willingness, determinants, and communication needs in gay, bisexual, and other men who have sex with men, in the context of limited vaccine availability in the Netherlands (Dutch Mpox-survey). Front Public Health. 2023;10:1058807. Published 2023 Jan 5. doi: 10.3389/fpubh.2022.1058807 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Dewan SMR, Islam MR. Increasing reinfections and decreasing effectiveness of COVID-19 vaccines urge the need for vaccine customization. Ann Med Surg (Lond). 2022;84:104961. doi: 10.1016/j.amsu.2022.104961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nazmunnahar, Ahmed I, Islam MR. Risk evaluation and mitigation strategies for newly detected SARS-CoV-2 Omicron BF.7 subvariant: A brief report. Health Sci Rep. 2023;6(3):e1127. Published 2023 Mar 2. doi: 10.1002/hsr2.1127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Haque MA, Tanbir M, Ahamed B, et al. Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. Clin Pathol. 2023;16:2632010X231161222. Published 2023 Mar 13. doi: 10.1177/2632010X231161222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Barai S, Kadir MF, Shahriar M, Islam MR. The re-emergence of COVID-19 in China is a big threat for the world: Associated risk factors and preventive measures. Ann Med Surg (Lond). 2023;85(2):348–350. Published 2023 Feb 7. doi: 10.1097/MS9.0000000000000219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Akif A, Bhuiyan MA, Islam MR. SARS-COV-2 Omicron subvariant BF.7 is again triggering the Covid fear: What we need to know and what we should do?. J Med Virol. 2023;95(2):e28551. doi: 10.1002/jmv.28551 [DOI] [PubMed] [Google Scholar]
  • 48.Dhama K, Nainu F, Frediansyah A, et al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J Infect Public Health. 2023;16(1):4–14. doi: 10.1016/j.jiph.2022.11.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. Clin Pathol. 2022;15:2632010X221075584. Published 2022 Feb 3. doi: 10.1177/2632010X221075584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Sohan M, Hossain MJ, Islam MR. The SARS-CoV-2 Omicron (B.1.1.529) variant and effectiveness of existing vaccines: What we know so far. J Med Virol. 2022;94(5):1796–1798. doi: 10.1002/jmv.27574 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Christian Napoli

10 Apr 2023

PONE-D-23-05498Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findingsPLOS ONE

Dear Dr. Islam,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 25 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for the opportunity to review the manuscript "Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings."

It is well-written, and the topic is relevant. I have only minor changes to further improve the quality of this paper.

1. The Material and methods section should better explain what the authors mean with the question regarding the impact of Covid-19 on the respondents’ life.

2. I believe that you should add in the limit of the study that you excluded females of all ages, as this is a clear selection bias.

3. I suggest to compare these results with more experiences that consider not only a possible MPXV vaccination, but the relationship between the general population and monkeypox virus as well, especially in European continent (see doi: https://doi.org/10.3390/pathogens11111285).

Reviewer #2: The authors have conducted a study which is irrelevant in the perspective of country where it is conducted. As of now, no cases of Monkey pox were reported in Bangladesh. Hence, why should one be concerned about vaccination when quick identification, isolation and management would be appropriate to prevent the spread of the disease. And if there is no plan to vaccinate people in near future, why one should be concerned about awareness regarding Mpox vaccine perception and acceptance?

Moreover, the description of result doesn't match with tables and figures.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 8;18(6):e0286322. doi: 10.1371/journal.pone.0286322.r002

Author response to Decision Letter 0


10 May 2023

Dear Editors and Reviewers,

Thank you for your letter and the reviewers' comments on our manuscript entitled "Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings" (Manuscript ID PONE-D-23-05498). All the comments were valuable and helpful to the revision and improvement of the manuscript. We have carefully studied the comments and made corrections, which we hope will merit your approval. We marked the revised portions using track changes. Our point-by-point answers to the reviewers’ comments appear at the end of this letter.

We earnestly appreciate the Editors'/Reviewers' work. We hope that after this revision, the paper will be deemed fit for publication. We would be glad to respond to any further questions and comments that you may have.

Once again, thank you very much for your comments and suggestions.

Best regards,

Md. Rabiul Islam, PhD

Associate Professor, Department of Pharmacy, University of Asia Pacific, 74/A Green Road, Farmgate, Dhaka-1205, Bangladesh. Email: robi.ayaan@gmail.com; Cell: +8801916031831

Point by point authors’ responses to the reviewers

Manuscript ID PONE-D-23-05498

Title: Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings

Reviewer #1

Thank you for the opportunity to review the manuscript "Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings."

It is well-written, and the topic is relevant. I have only minor changes to further improve the quality of this paper.

Author’s response

Thank you for your review and encouraging comments on our manuscript. We have addressed all your observation very carefully in our revised manuscript.

Comment 1. The Material and methods section should better explain what the authors mean with the question regarding the impact of Covid-19 on the respondents’ life.

Author’s response

Thank you for your observation. We have now included more information about the impact of Covid-19 on the respondents’ life in the method section for better understanding of readers (page 6, line 19-20).

Comment 2. I believe that you should add in the limit of the study that you excluded females of all ages, as this is a clear selection bias.

Author’s response

Thank you for your suggestion. We have explained about the inclusion of only males in this study based on the disease epidemiology and prevalence (page 6, lines 3-6).

“Only adult males were invited to participate in this study of ages ranging from 18 to 45 years as this age is vulnerable to the Mpox virus. Moreover, several data studies around the world showed 98% of confirmed cases of Mpox disease among 18-45 years of males. Therefore, we excluded females of all ages.”

However, we have added this point as a limitation of this study to avoid selection biasness (page 18, lines 9-10).

Comment 3. I suggest to compare these results with more experiences that consider not only a possible MPXV vaccination, but the relationship between the general population and monkeypox virus as well, especially in European continent (see doi: https://doi.org/10.3390/pathogens11111285).

Author’s response

Thank you again for your valuable suggestion. We have now compared our results with the suggested study finding in Europe (page 16, line 21-24).

Reviewer #2

The authors have conducted a study which is irrelevant in the perspective of country where it is conducted. As of now, no cases of Monkey pox were reported in Bangladesh. Hence, why should one be concerned about vaccination when quick identification, isolation and management would be appropriate to prevent the spread of the disease. And if there is no plan to vaccinate people in near future, why one should be concerned about awareness regarding Mpox vaccine perception and acceptance?

Moreover, the description of result doesn't match with tables and figures.

Author’s response

Thank you for your review and opinion about this manuscript. We have conducted this study regarding Mpox vaccine perception and vaccination intention in Bangladesh where there is no reported case of Mpox infection. Bangladesh is a densely populated lower middle-income country (total population is 169.35 million). The population density in Bangladesh is 1265 per Km2 (3,277 people per mi2). The median age in Bangladesh is 27.6 years. It is difficult to control infectious disease outbreak in such country with large population and weak healthcare infrastructure. Therefore, preventive measures might be a good option for Bangladesh. We conducted this study to report vaccine perception and vaccination intention of Bangladeshi population so that the authorities can know and take necessary measures. Moreover, we totally agree that quick identification, isolation and management are appropriate to prevent the spread of infectious disease. But according to our own experience during Covid-19 pandemic, it was almost impossible to implement these measures in Bangladesh for high population load and literacy level of general people. What Bangladesh did, the country achieved high success in rolling out Covid-19 vaccination (more than 90% people vaccinated). Therefore, the country did face any big threat due to the recent past pandemic. I this context the present study is relevant and useful for the healthcare authorities, policymakers, and others.

Also, we have corrected some mismatch about the description of result with tables and figures in the revised manuscript.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Christian Napoli

15 May 2023

Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings

PONE-D-23-05498R1

Dear Authors,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

The Academic Editor

PLOS ONE

Acceptance letter

Christian Napoli

31 May 2023

PONE-D-23-05498R1

Assessment of vaccine perception and vaccination intention of Mpox infection among the adult males in Bangladesh: A cross-sectional study findings

Dear Dr. Islam:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Christian Napoli

Academic Editor

PLOS ONE


Articles from PLOS ONE are provided here courtesy of PLOS

RESOURCES